{"id":877645,"date":"2025-08-20T16:41:42","date_gmt":"2025-08-20T20:41:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-second-quarter-2025-financial-results-and-provides-business-update\/"},"modified":"2025-08-20T16:41:42","modified_gmt":"2025-08-20T20:41:42","slug":"nucana-reports-second-quarter-2025-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-second-quarter-2025-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Additional Data from the Ongoing Phase 1b\/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 <\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

\u201cWe are pleased to announce that the first patients have been dosed on the expansion of our ongoing Phase 1\/2 NuTide:701 study in patients with PD-1 inhibitor-resistant melanoma,\u201d said Andrew Kay, NuCana\u2019s Executive Chairman. \u201cOur lead program, NUC-7738 is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. We remain encouraged by the clinical observations witnessed so far. We have observed a favorable safety profile, meaningful tumor volume reduction and prolonged progression free-survival in patients with PD-1 inhibitor refractory and resistant metastatic melanoma. The expansion study is expected to enroll an additional 28 patients, increasing the planned patient population treated in combination with pembrolizumab to 40 and further supporting our registrational path.\u201d<\/p>\n

Mr. Kay continued, \u201cTurning to our second program, NUC-3373 is a targeted thymidylate synthase inhibitor with immune modulating properties. We are encouraged by the data from the Phase 1b\/2 NuTide:303 study, which is evaluating NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors, and NUC-3373 with docetaxel in patients with lung cancer. Notable tumor volume reductions and prolonged progression free survival have been observed in these patients so far. We look forward to announcing additional data from this study later this year.\u201d<\/p>\n

Mr. Kay concluded, \u201cLastly, we strengthened our balance sheet with a financing in May and the strategic execution of an at-the-market (\u201cATM\u201d) offering, extending our cash runway into 2029 and through key value-driving milestones. To date in 2025, these initiatives have raised gross proceeds of $38.4 million and with multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.\u201d<\/p>\n

\n Anticipated Milestones<\/strong>\n <\/p>\n